In further experimental models, the combination of PTEN loss with ERG over-expression or Tp53 mutation has been shown to promote the transition to invasive prostate carcinoma [6,7] while epidemiological studies conform the relevance of PTEN to aggressive prostate cancer [8]. This evidence concerns the gene PTEN and prostate carcinoma.